Browsing Tag
Spur Therapeutics
2 posts
Syncona’s £1.04bn NAV faces 2026 clinical test as £250m capital-return strategy takes shape
Syncona is targeting at least £250 million of shareholder returns as four 2026 biotech catalysts test whether its £1.04 billion NAV can finally translate into realised cash.
How skeletal endpoints are becoming central to Gaucher disease innovation strategies
FLT201 data shifts focus to skeletal endpoints in Gaucher disease. Discover what this means for gene therapy strategy and market competition.